 |
Katherine L. Wisner, MD, MS - SSRIs during pregnancy: The evolving story |
 |
Christina Chambers, PhD, MPH - Teratology networks and their power to inform decisions |
 |
Parvaz Madadi, PhD Candidate - CYP2D6 and it’s important role in pregnancy therapy individualization |
|
|
 |
James J. Nocon, MD, JD - Treatment of Substance Use in Pregnancy |
|
|
 |
Lang Li, PhD - A PG/DDI/Physiology Model- Its potential utility for Individualized pharmacotherapy in pregnancy |
|
|
 |
Gary D. Hankins, MD - Pregnancy: Unique Physiology, Unique Pathology |
|
|
 |
Lee A. Learman, MD, PhD - Conceptual model of the future: Individualizing pharmacoRx in pregnany |
 |
Offie P. Soldin, PhD - Management of Thyroid Disease in Pregnancy |
|
|
|
Mary Hebert, PharmD - The Clinical Relevance of Pharmacokinetic Changes in Pregnancy |
|
|
|
David Flockhart MD, PhD - Pharmacogenetics as a Biomarker and the Potential for Pregnancy
|
|
|
|
Panel Discussion - First Trimester Medication Issues
|
|
|
|
Second Panel Discussion - What have we learned and what comes next?
|
|
|
